Everest marks a new chapter in market confidence as Hong Kong Exchange grants removal of its “B” designation.

NEFECON®, as the only approved IgAN therapy in China, generated RMB353.4 million in revenue for the year, representing a year-over-year increase of 1,581%. NEFECON® was also included in China’s ...

University of Delaware's Mona Batish is a molecular biologist. She studies circular RNAs formed as a result of so-called ...

South Korean researchers have, for the first time in the world, uncovered how messenger ribonucleic acid (mRNA) vaccines enter human cells, function inside the body, and are blocked by certain ...

The issuer is solely responsible for the content of this announcement.

As the lines between beauty, health and tech blur, future product innovation will be driven by regenerative science and ...

This photo taken with a mobile phone shows a volunteer (R) helping Yemeni businessman Sufyan Marwan Sufyan Mohanmmed take vaccine reservation receipt for his ...

The SCOPE study of iSCIB1+, an off-the-shelf DNA plasmid vaccine that will be tested in combination with checkpoint ...

Big Pharma-backed Atalanta Therapeutics is ramping up for the clinical debut of the company’s lead epilepsy asset in the wake ...

Another company looking to initiate clinical trials with an epigenetic-editor-based treatment for hepatitis is nChroma Bio.